Compass Therapeutics posts $14.3 million net loss for third quarter 2025

Reuters11-05

Compass <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts $14.3 million net loss for third quarter 2025

Compass Therapeutics Inc. reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $50.8 million, up from $34.3 million in the prior year period. Research and development expenses increased by 44% to $42.3 million for the nine months ended September 30, 2025, primarily due to higher manufacturing and IND-enabling costs related to tovecimig and CTX-10726. Other income decreased by 29% to $3.9 million for the nine months ended September 30, 2025, due to lower interest income from reduced average cash and marketable securities balances. The company has not generated revenue from the sale of products and continues to fund operations primarily through equity securities, with $568 million raised in gross proceeds to date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007005), on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581722841?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581722841","market":"nz","top_or_hot":-1,"title":"Compass Therapeutics posts $14.3 million net loss for third quarter 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posts $14.3 million net loss for third quarter 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Therapeutics Inc. reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $50.8 million, up from $34.3 million in the prior year period. Research and development expenses increased by 44% to $42.3 million for the nine months ended September 30, 2025, primarily due to higher manufacturing and IND-enabling costs related to tovecimig and CTX-10726. Other income decreased by 29% to $3.9 million for the nine months ended September 30, 2025, due to lower interest income from reduced average cash and marketable securities balances. The company has not generated revenue from the sale of products and continues to fund operations primarily through equity securities, with $568 million raised in gross proceeds to date.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007005), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics posts $14.3 million net loss for third quarter 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics posts $14.3 million net loss for third quarter 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> posts $14.3 million net loss for third quarter 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Therapeutics Inc. reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $50.8 million, up from $34.3 million in the prior year period. Research and development expenses increased by 44% to $42.3 million for the nine months ended September 30, 2025, primarily due to higher manufacturing and IND-enabling costs related to tovecimig and CTX-10726. Other income decreased by 29% to $3.9 million for the nine months ended September 30, 2025, due to lower interest income from reduced average cash and marketable securities balances. The company has not generated revenue from the sale of products and continues to fund operations primarily through equity securities, with $568 million raised in gross proceeds to date.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007005), on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPX","symbol_name":"Compass Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLZMQL6:1","article_id":"2581722841","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581722841","pubTimestamp":1762345904,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Therapeutics Inc. reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $50.8 million, up from $34.3 million in the prior year period. Research and development expenses increased by 44% to $42.3 million for the nine months ended September 30, 2025, primarily due to higher manufacturing and IND-enabling costs related to tovecimig and CTX-10726. Other income decreased by 29% to $3.9 million for the nine months ended September 30, 2025, due to lower interest income from reduced average cash and marketable securities balances. The company has not generated revenue from the sale of products and continues to fund operations primarily through equity securities, with $568 million raised in gross proceeds to date.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPX":"Compass Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Compass Therapeutics公布2025年第三季度净亏损1,430万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":0.9},"content_text":"Compass Therapeutics posts $14.3 million net loss for third quarter 2025\n    \n\n        Compass Therapeutics Inc. reported a net loss of $14.3 million for the three months ended September 30, 2025, compared to a net loss of $10.5 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $50.8 million, up from $34.3 million in the prior year period. Research and development expenses increased by 44% to $42.3 million for the nine months ended September 30, 2025, primarily due to higher manufacturing and IND-enabling costs related to tovecimig and CTX-10726. Other income decreased by 29% to $3.9 million for the nine months ended September 30, 2025, due to lower interest income from reduced average cash and marketable securities balances. The company has not generated revenue from the sale of products and continues to fund operations primarily through equity securities, with $568 million raised in gross proceeds to date.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007005), on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581722841","isCrawlerRequest":true}